642 related articles for article (PubMed ID: 8941648)
41. A Novel Hexavalent Capsular Polysaccharide Conjugate Vaccine (GBS6) for the Prevention of Neonatal Group B Streptococcal Infections by Maternal Immunization.
Buurman ET; Timofeyeva Y; Gu J; Kim JH; Kodali S; Liu Y; Mininni T; Moghazeh S; Pavliakova D; Singer C; Singh S; Handke LD; Lotvin J; Prasad AK; Scully IL; Donald RGK; Jansen KU; Anderson AS
J Infect Dis; 2019 Jun; 220(1):105-115. PubMed ID: 30778554
[TBL] [Abstract][Full Text] [Related]
42. Therapeutic potential of human antisera to group B streptococcal glycoconjugate vaccines in neonatal mice.
Paoletti LC; Pinel J; Rodewald AK; Kasper DL
J Infect Dis; 1997 May; 175(5):1237-9. PubMed ID: 9129094
[TBL] [Abstract][Full Text] [Related]
43. A randomized trial of conjugated group B streptococcal type Ia vaccine in a rabbit model of ascending infection.
Davies JK; Paoletti LC; McDuffie RS; Madoff LC; Lee S; Eskens J; Gibbs RS
Am J Obstet Gynecol; 1999 Oct; 181(4):803-8. PubMed ID: 10521733
[TBL] [Abstract][Full Text] [Related]
44. Conjugation of β-glucan markedly increase the immunogencity of meningococcal group Y polysaccharide conjugate vaccine.
Qiao W; Ji S; Zhao Y; Hu T
Vaccine; 2015 Apr; 33(17):2066-72. PubMed ID: 25728319
[TBL] [Abstract][Full Text] [Related]
45. Neither antibody to a group B streptococcal conjugate vaccine nor the vaccine itself is teratogenic in rabbits.
Paoletti LC; Guttormsen HK; Christian MS; Hoberman AM; McInnes P
Hum Vaccin; 2008; 4(6):435-43. PubMed ID: 18443428
[TBL] [Abstract][Full Text] [Related]
46. Class specificity of naturally acquired and vaccine-induced antibody to type III group B streptococcal capsular polysaccharide: determination with a radioimmunoprecipitin assay.
Edwards MS; Fuselier PA; Rench MA; Kasper DL; Baker CJ
Infect Immun; 1984 May; 44(2):257-61. PubMed ID: 6370863
[TBL] [Abstract][Full Text] [Related]
47. Structural properties of group B streptococcal type III polysaccharide conjugate vaccines that influence immunogenicity and efficacy.
Wessels MR; Paoletti LC; Guttormsen HK; Michon F; D'Ambra AJ; Kasper DL
Infect Immun; 1998 May; 66(5):2186-92. PubMed ID: 9573106
[TBL] [Abstract][Full Text] [Related]
48. Group B streptococcal vaccines.
Baker CJ; Kasper DL
Rev Infect Dis; 1985; 7(4):458-67. PubMed ID: 3898306
[TBL] [Abstract][Full Text] [Related]
49. Capsular switching in group B Streptococcus CC17 hypervirulent clone: a future challenge for polysaccharide vaccine development.
Bellais S; Six A; Fouet A; Longo M; Dmytruk N; Glaser P; Trieu-Cuot P; Poyart C
J Infect Dis; 2012 Dec; 206(11):1745-52. PubMed ID: 23002446
[TBL] [Abstract][Full Text] [Related]
50. Functional activity of maternal and cord antibodies elicited by an investigational group B Streptococcus trivalent glycoconjugate vaccine in pregnant women.
Fabbrini M; Rigat F; Tuscano G; Chiarot E; Donders G; Devlieger R; Filippini S; Frigimelica E; Forte P; Wittke F; Halperin SA; Slobod K; Grandi G; Margarit I
J Infect; 2018 May; 76(5):449-456. PubMed ID: 29374589
[TBL] [Abstract][Full Text] [Related]
51. Immunogenicity of group B Streptococcus type III polysaccharide-tetanus toxoid vaccine in baboons.
Paoletti LC; Kennedy RC; Chanh TC; Kasper DL
Infect Immun; 1996 Feb; 64(2):677-9. PubMed ID: 8550227
[TBL] [Abstract][Full Text] [Related]
52. Group B Streptococcus capsular polysaccharide-cholera toxin B subunit conjugate vaccines prepared by different methods for intranasal immunization.
Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
Infect Immun; 2001 Jan; 69(1):297-306. PubMed ID: 11119518
[TBL] [Abstract][Full Text] [Related]
53. Sublingual immunisation with GBS serotype III capsular polysaccharide-tetanus toxoid conjugate vaccine induces systemic and mucosal antibody responses which are opsonophagocytic and inhibit GBS colonisation of vaginal epithelial cells.
Deifallah Yousif M; Felek A; Saydam M; Wilson S; Murdan S; Mawas F
Vaccine; 2022 Oct; 40(42):6055-6063. PubMed ID: 36096970
[TBL] [Abstract][Full Text] [Related]
54. Estimation of group B streptococcus type III polysaccharide-specific antibody concentrations in human sera is antigen dependent.
Bhushan R; Anthony BF; Frasch CE
Infect Immun; 1998 Dec; 66(12):5848-53. PubMed ID: 9826364
[TBL] [Abstract][Full Text] [Related]
55. A randomized, observer-blind Phase Ib study to identify formulations and vaccine schedules of a trivalent Group B Streptococcus vaccine for use in non-pregnant and pregnant women.
Leroux-Roels G; Maes C; Willekens J; De Boever F; de Rooij R; Martell L; Bedell L; Wittke F; Slobod K; Dull P
Vaccine; 2016 Apr; 34(15):1786-91. PubMed ID: 26928074
[TBL] [Abstract][Full Text] [Related]
56. Novel Multiplex Immunoassays for Quantification of IgG against Group B
Buffi G; Galletti B; Stella M; Proietti D; Balducci E; Romano MR; Mori E; Fabbrini M; Giuliani MM; Berti F; Margarit I
mSphere; 2019 Aug; 4(4):. PubMed ID: 31391276
[TBL] [Abstract][Full Text] [Related]
57. Vaccines to prevent neonatal GBS infection.
Paoletti LC; Madoff LC
Semin Neonatol; 2002 Aug; 7(4):315-23. PubMed ID: 12401301
[TBL] [Abstract][Full Text] [Related]
58. Immunization with C5a peptidase or peptidase-type III polysaccharide conjugate vaccines enhances clearance of group B Streptococci from lungs of infected mice.
Cheng Q; Debol S; Lam H; Eby R; Edwards L; Matsuka Y; Olmsted SB; Cleary PP
Infect Immun; 2002 Nov; 70(11):6409-15. PubMed ID: 12379721
[TBL] [Abstract][Full Text] [Related]
59. Designer vaccines to prevent infections due to group B Streptococcus.
Kasper DL
Proc Assoc Am Physicians; 1995 Oct; 107(3):369-73. PubMed ID: 8608425
[TBL] [Abstract][Full Text] [Related]
60. Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in hemodialysis patients.
Fattom A; Fuller S; Propst M; Winston S; Muenz L; He D; Naso R; Horwith G
Vaccine; 2004 Dec; 23(5):656-63. PubMed ID: 15542186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
